Stifel Financial Corp Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

Stifel Financial Corp lowered its position in MacroGenics, Inc. (NASDAQ:MGNX) by 35.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 25,861 shares of the biopharmaceutical company’s stock after selling 14,027 shares during the quarter. Stifel Financial Corp’s holdings in MacroGenics were worth $84,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MGNX. XML Financial LLC grew its holdings in MacroGenics by 31.6% during the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 5,569 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of MacroGenics by 45.4% during the fourth quarter. Wells Fargo & Company MN now owns 29,838 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 9,312 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of MacroGenics during the fourth quarter worth about $38,000. Marshall Wace LLP grew its holdings in shares of MacroGenics by 3.2% during the fourth quarter. Marshall Wace LLP now owns 393,766 shares of the biopharmaceutical company’s stock worth $1,280,000 after purchasing an additional 12,250 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of MacroGenics by 13.3% during the fourth quarter. Barclays PLC now owns 111,891 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 13,138 shares in the last quarter. Hedge funds and other institutional investors own 96.89% of the company’s stock.

MacroGenics Price Performance

Shares of MGNX opened at $1.58 on Friday. The firm has a market cap of $99.68 million, a P/E ratio of -1.00 and a beta of 2.20. The stock has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $2.61. MacroGenics, Inc. has a 1 year low of $0.99 and a 1 year high of $5.77.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The company had revenue of $13.19 million during the quarter, compared to the consensus estimate of $9.59 million. On average, equities analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MGNX. Barclays reissued an “overweight” rating and set a $3.00 price objective (down previously from $8.00) on shares of MacroGenics in a report on Wednesday. Stifel Nicolaus cut their price objective on MacroGenics from $6.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday. StockNews.com lowered MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Finally, HC Wainwright cut their price objective on MacroGenics from $4.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, March 25th. Eight equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, MacroGenics currently has a consensus rating of “Hold” and an average price target of $6.38.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.